Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc
$MDXG
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/2/2024 | $11.00 | Overweight | Cantor Fitzgerald |
| 3/7/2024 | $12.00 | Buy | Lake Street |
| 10/27/2023 | $12.00 | Buy | Craig Hallum |
| 10/13/2022 | $7.00 | Buy | Mizuho |
| 9/14/2021 | $20.00 → $8.50 | Buy | HC Wainwright & Co. |
| 7/26/2021 | $23.00 | Outperform | Northland Capital |
Net Sales of $84 million Grew 3% Year-Over-Year for the Third QuarterThird Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, RespectivelyThird Quarter Adjusted EBITDA was $18 Million, or 22% of Net SalesRaises 2024 Net Sales Growth Expectations to the High Single-DigitsManagement to Host Conference Call Today, October 30, 2024, at 4:30 PM ET MARIETTA, Ga., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the third quarter 2024. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our solid third quarter 2024 results include total net sales growth of 3% year-
MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the third quarter ended September 30, 2024 after the market close on Wednesday, October 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13748866 A replay of the webcast will be available for approximately 30 days on the Company's
Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12, Respectively Second Quarter Adjusted EBITDA was $20 Million, or 23% of Net Sales Management to Host Conference Call Today, July 31, 2024, at 4:30 PM ET MARIETTA, Ga., July 31, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2024. Recent Operating and Financial Highlights: Second quarter 2024 net sales of $87 million, reflecting 7% growth over the prior year period.GAAP net income from continuing operat
SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)
SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a
MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020. "I am pleased to announce this well-deserved promotion of Kim to Chief Commercial Officer for MIMEDX," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Under Kim's leadership as SVP of Sales for the past four years, the MIMEDX commercial organization has navigated significant change and has been transformed into the high-performing team we have today. As we continue to work our way through a period of swe
MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors. M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, "On behalf of the entire Board of Directors, we are honored to welcome these a
MARIETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following investor conferences: Stifel Healthcare Conference 2024Webcast (9:45 AM ET): Click here to accessMonday, November 18, 2024New York, NY 15th Annual Craig-Hallum Alpha Select ConferenceTuesday, November 19, 2024New York, NY Investors interested in meeting with senior management at these events may contact their respective Stifel or Craig-Hallum representative. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic
Net Sales of $84 million Grew 3% Year-Over-Year for the Third QuarterThird Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, RespectivelyThird Quarter Adjusted EBITDA was $18 Million, or 22% of Net SalesRaises 2024 Net Sales Growth Expectations to the High Single-DigitsManagement to Host Conference Call Today, October 30, 2024, at 4:30 PM ET MARIETTA, Ga., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the third quarter 2024. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our solid third quarter 2024 results include total net sales growth of 3% year-
MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the third quarter ended September 30, 2024 after the market close on Wednesday, October 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13748866 A replay of the webcast will be available for approximately 30 days on the Company's
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
3 - MIMEDX GROUP, INC. (0001376339) (Issuer)
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
Cantor Fitzgerald initiated coverage of MiMedx Group with a rating of Overweight and set a new price target of $11.00
Lake Street initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00
Craig Hallum initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00
4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
Cantor Fitzgerald has initiated coverage on MiMedx Group Inc. (NASDAQ:MDXG), a provider of a product portfolio for applications in wound care, burn, and surgical recovery. The analyst notes that MIMEDX’s technologies target a $3.9 billion market that will grow at a 5% CAGR to $4.9 billion in 2028. In Advanced Wound Care, MIMEDX concentrates on the rapidly expanding skin substitutes market, which is projected to grow at a 12% CAGR from $1.1 billion in 2021 to $2.0 billion by 2026, Cantor cites BCC Research. Additionally, MIMEDX anticipates the Surgical Wound Care market, which will increase at a 3% CAGR from $2.1 billion in 2023 to $2.5 billion by 2026. Cantor initiates with an Overw
Cantor Fitzgerald analyst Ross Osborn initiates coverage on MiMedx Group (NASDAQ:MDXG) with a Overweight rating and announces Price Target of $11.
8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
10-Q - MIMEDX GROUP, INC. (0001376339) (Filer)
144 - MIMEDX GROUP, INC. (0001376339) (Subject)